Clinical Trial Update: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial evaluates the safety and efficacy of JCAR017 in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma and is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• JCAR017

Snippet

Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic | Phase 1, Phase 2 | Status: RECRUITING